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Abstract
Background—Embarrassment is a commonly described feature of essential tremor (ET) but has
not been the focus of clinical research.
Objective—To estimate the prevalence, identify susceptible patient groups, and quantify the
therapeutic correlates of reported embarrassment.
Methods—106 ET cases from a population-based sample and 349 ET cases from a clinical sample
were asked, “Does your tremor often embarrass you?”
Results—In the clinical sample, the prevalence of embarrassment was high (58.2%). Even in those
ET cases with no head tremor and mild arm tremor, nearly one-half (29/61 [47.5%]) reported
embarrassment. While the prevalence of embarrassment was lower in the population-based sample,
it was not negligible (18.9%). Embarrassment was associated with younger age of onset (p = 0.003)
and women were nearly twice as likely as men to report embarrassment (OR = 1.85, p = 0.01).
Independent of tremor severity, embarrassment nearly doubled the odds of using tremor medication
(OR = 1.86, p = 0.01).
Conclusions—Embarrassment may be a source of disability in ET. Even among clinic patients
with mild tremor, nearly one-half reported embarrassment. We identified a number of patient
characteristics linked to embarrassment. Embarrassment alone (i.e., independent of tremor severity)
was responsible for a doubling of tremor medication usage. The majority of clinical trials do not
assess the therapeutic effects of medication on embarrassment. These trials may benefit from scaled
assessments of level of embarrassment.
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Quality of life issues are now looming large in movement disorders [1], and it is important to
understand the impact of disease on quality of life. Embarrassment about tremor is anecdotally
well-known to occur in patients with essential tremor (ET) and is likely a prime motivating
feature driving treatment and enrollment in clinical trials.
Embarrassment is a unique psychological construct that may be defined as an experience upon
having an unacceptable act or condition witnessed by or revealed to others; it is often associated
with some amount of loss of honor or dignity. Embarrassment is a source of distress for patients;
furthermore, it may result in social handicap and possibly social phobia [2]. Thus,
embarrassment itself may be a direct source of disability. It has also been shown that
unalleviated embarrassment may remain as an unmet treatment need in many ET patients even
after drug therapy has substantially improved their handwriting, drinking, and eating [3].
Hence, understanding embarrassment is important. Despite this, it has not been studied in ET.
Little is known of its prevalence or about those patient subgroups who are most susceptible.
Furthermore, the relationships between embarrassment, tremor severity and patient
motivations to initiate treatment have not been formally quantified.
Our knowledge of embarrassment in ET is mainly anecdotal. The few existing data have been
derived from small datasets exclusively from treatment settings. In a study of 18 ET patients
attending a treatment center, 8 (44.4%) reported embarrassment, including all patients with
head tremor [3]. Of 43 male military veterans seeking treatment for ET, 32 (74.4%) reported
embarrassment [4]. In a study of 34 ET patients at a treatment center, “many” complained of
embarrassment [5]. Patient susceptibility groups and therapeutic implications of
embarrassment have not been assessed in the literature.
We studied embarrassment in ET in order to: (1) estimate its prevalence in two large yet distinct
case samples, one from a population (N = 106) and the second from a clinical sample (N =
349). Furthermore, in the clinical sample, we aimed to: (2) establish its clinical correlates (i.e.,
characterize patient susceptibility groups), and (3) understand and begin to quantify the
associations between embarrassment and tremor severity on the one hand and the decision to
treat tremor on the other.
Methods
All enrollees signed written informed consent as approved by our institutional ethics board.
Population-based Sample
The Washington Heights-Inwood Genetic Study of Essential Tremor was a family study of ET
in the Washington Heights-Inwood community in northern Manhattan, New York. Enrollment
was completed in 2000, at which time there were 106 ET cases (59 probands with ET, 33 of
their relatives with ET, and 14 affected relatives of control probands). The design of this
population-based study has been described in detail elsewhere [6]; in brief, probands with ET
age 65 and older were sampled from the Washington Heights-Inwood community and were
included if they had a diagnosis of ET. Presence or absence of depression or anxiety was not
an enrollment criterion. All cases underwent demographic and medical histories and a
videotaped tremor examination, which included one test to assess postural tremor (sustained
arm extension) and five tests to assess kinetic tremor (finger-nose-finger, pouring, drinking,
using a spoon, drawing spirals)[6]. Each of the six tests was performed with the dominant arm
and then the nondominant arm, resulting in 12 tests total. Each videotape was reviewed by a
neurologist specializing in movement disorders (E.D.L.) who was blinded to clinical data, and
the tremor was rated during each test using a 0 – 3 clinical rating scale. Thereby, each participant
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was assigned a total tremor score (range = 0 – 36 maximal tremor). Early in the medical history,
all cases were asked, “Does your tremor often embarrass you?”
Clinical Sample
ET cases from the Neurological Institute of New York, Columbia University Medical Center
are being enrolled in an ongoing study of the environmental epidemiology of ET (2000 –
present); the design of this study has been described in detail previously [7]. Briefly, prior to
enrollment, all cases were diagnosed with ET by their neurologist. Presence or absence of
depression or anxiety was not an enrollment criterion. After enrollment, all 349 cases
underwent a single evaluation that included a series of questionnaires (including a question as
to whether they used tremor medications, a tremor disability scale [range = 0 – 100 maximal
impairment][8] and Cumulative Illness Rating Scale [CIRS, range = 0 – 42 maximal
comorbidity][9]), a performance-based test of function (range = 0 – 100 [maximal difficulty])
[8], and a videotaped tremor examination [7]. Early in the medical history, all cases were asked,
“Does your tremor often embarrass you?”
Statistical Analyses
Data for each aim were analyzed in SPSS (Version 15.0). Confidence intervals were computed
for several point estimates.
Results
Prevalence of Embarrassment
There were 106 ET cases in the population-based sample (mean ± SD age = 69.8 ± 18.4 years;
63[59.4%] women; age of tremor onset = 56.7 ± 25.6 years; tremor duration = 15.4 ± 18.8
years; total tremor score = 17.6 ± 6.5). Twenty (18.9%) of 106 reported embarrassment (95%
CI = 12.6% – 27.4%).
There were 349 ET cases in the clinical sample (age = 67.2 ± 15.3 years; 178[51.0%] women;
age of tremor onset = 44.9 ± 22.5 years; tremor duration = 22.6 ± 18.6 years; total tremor score
= 18.8 ± 7.2). Compared to the population sample, a larger proportion (203 or 58.2%, 95% CI
= 52.9% – 63.2%) reported embarrassment (chi-square = 50.25, p < 0.001).
Clinical Correlates of Embarrassment (Clinical Sample)
In univariate analyses, ET cases who reported embarrassment differed from those who did not
report embarrassment in demographic factors (younger age, female gender, lower education)
and several disease characteristics (younger age of tremor onset, longer tremor duration, family
history of ET or tremor, higher total tremor score, greater tremor disability, poorer
performance-based test results, voice tremor, and greater medication usage)(Table 1). In
multivariate logistic regression analyses, a smaller number of factors emerged that best
identified patients who were more susceptible to embarrassment (for final model, p < 0.001).
In the final model, embarrassment (dependent variable) was associated with female gender
(odds ratio [OR] = 1.85, 95% CI = 1.16 – 2.96, p = 0.01 [i.e., women were nearly twice as
likely as men to be embarrassed, and this was independent of presence or absence of head
tremor and arm tremor severity]), younger age of tremor onset (OR = 0.98, 95% CI = 0.97 –
0.99, p = 0.003 [i.e., with each 10-year reduction, the odds of embarrassment increased by
20%]), and greater tremor disability scale score (OR = 1.02, 95% CI = 1.01 – 1.03, p < 0.001
[i.e., with each 10% increase in the disability scale score, there was a 20% increased odds of
embarrassment]).
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We further stratified ET cases into total tremor score quartiles. Even when we selected ET
cases with no head tremor and mild arm tremor (total tremor score in lowest quartile !14),
nearly one-half (29/61 [47.5%]) reported embarrassment.
Embarrassment, Tremor Severity and Use of Tremor Medication (Clinical Sample)
In univariate analyses, we examined the predictors of current tremor medication use (dependent
variable); these were total tremor score, tremor disability scale score, performance-based test
score, reported embarrassment and family history (Table 2). In multivariate analyses, two
factors emerged, which were associated with an increased odds of using tremor medication:
higher total tremor score (OR = 1.04, 95% CI = 1.002 – 1.08, p = 0.04, i.e., with each ten point
increase in the total tremor score, the odds of using tremor medication increased by 40%) and
reported embarrassment (OR = 1.86, 95% CI = 1.15 – 3.01, p = 0.01, i.e., independent of tremor
severity, reported embarrassment was associated with an 86% increased odds of using tremor
medication).
Discussion
The prevalence of embarrassment depended on the method of case ascertainment. In a clinical
sample, it was a feature of more than one-half (58.2%), though not all, cases. This high
prevalence is not surprising in a group of self-referred cases attending a treatment center. Yet
even in a population-based sample, while the prevalence was only one-third of that seen in a
treatment setting, at 18.9%, it was not negligible.
One limitation of this study is that we assessed embarrassment using a single question; the
degree of embarrassment was not graded. Hence, our analyses focused on factors associated
with the presence or absence of embarrassment rather than the severity of embarrassment.
Within this limited scope, we identified several factors that were associated with
embarrassment in initial univariate analyses and, in further multivariate modeling, a smaller
number of factors emerged that identified patients who were most susceptible to
embarrassment. Of interest is that women were twice as likely as men to report embarrassment,
and this was completely independent of presence or absence of head tremor or arm tremor
severity. Furthermore, younger age of onset was also associated with increased odds of
embarrassment. We had hypothesized the converse (i.e., less embarrassment with more time
to come to terms with their condition). Perhaps the presence of tremor at an early age leads to
greater sensitization.
While there was an association between embarrassment and tremor severity, our analyses also
indicated that embarrassment was not merely a by-product of severe tremor. Even among the
subgroup of ET cases who had mild arm tremor and no head tremor, nearly one-half (47.5%)
reported embarrassment. These data indicate that embarrassment is an important independent
factor to be reckoned with in treatment settings. Indeed, embarrassment was associated with
an 86% increased odds of using tremor medication and this was independent of tremor severity.
Embarrassment scales for ET do not exist; however, they would be beneficial in the clinical
assessment of patients. Such scales could be adapted from existing literature on the social
stigmata of other medical illnesses (e.g., epilepsy, obesity, and stress incontinence).
This study had limitations. If our question had asked whether tremor is “sometimes” rather
than “often” embarrassing, prevalence estimates would have been higher. Second,
embarrassment was assessed with a single question rather than a series of questions as no such
series exist for ET. The use of a single question likely resulted in lower reliability and sensitivity
and did not allow for correlations between degree of embarrassment and other clinical
correlates. Third, our cases were seen at one time point; it would be useful for future studies
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to evaluate changes in embarrassment over time. Finally, additional studies are needed to more
fully assess the relationships between embarrassment and other psychosocial issues such as
social phobia, depression, anxiety, and health-related quality of life.
In summary, embarrassment may be a source of disability in ET and a barrier to successful
treatment (i.e., patients may have remaining embarrassment-related distress despite having a
medication-related reduction in tremor amplitude). Even among clinic patients with mild
tremor, nearly one-half reported embarrassment. Women and young-onset cases were
particularly susceptible. Embarrassment nearly doubled the odds that a patient was taking a
tremor medication; interestingly, this was independent of the severity of the tremor. The
majority of clinical trials do not assess the therapeutic effects of medication on embarrassment.
Clinical trials of ET may wish to provide scaled assessments of level of embarrassment as well
as pre-treatment and post-treatment comparisons of these levels.
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Table 1
Clinical features of ET cases who report embarrassment s vs. ET cases who do not report embarrassment
ET cases who reported
embarrassment (n = 203)
ET cases who did not report
embarrassment (n = 146) Significance (p value)
Age in years 65.5 ± 16.2 69.5 ± 13.8 0.02a
Female Gender 115 (56.7%) 63 (43.2%) 0.01b
OR = 1.7 (1.1 – 2.7)
White Race 188 (92.6%) 140 (95.9%) 0.20b
Education (years) 14.7 ± 3.8 15.5 ± 3.9 0.050a
Age of tremor onset in years 40.8 ± 22.9 (n = 198) 50.4 ± 20.8 <0.001a
Tremor duration in years 25.2 ± 18.9 (n = 198) 19.1 ± 17.6 0.003a
First- or second-degree relative with ET or tremor 138 (68.0%) 80 (54.8%) 0.01b
OR = 1.8 (1.1 – 2.7)
Currently takes daily medication for tremor 112 (55.2%) 56 (38.4%) 0.002b
OR = 2.0 (1.3 – 3.1)
Total tremor score 19.9 ± 7.5 17.4 ± 6.4 0.001a
Tremor disability scale score 59.0 ± 28.6 (n = 202) 41.1 ± 27.6 (n = 140) <0.001a
Performance-based test score* 34.3 ± 22.2 (n = 116) 26.2 ± 19.3 (n = 75) 0.01a
CIRS score 5.6 ± 3.7 5.5 ± 3.6 (n = 141) 0.76a
Head tremor by history 78 (38.6%) (n = 202) 44 (30.3%) (n = 145) 0.11b
OR = 1.4 (0.92 – 2.3)
Head tremor on exam 83 (40.9%) 50 (34.2%) 0.21b
Voice tremor by history 49 (24.1%) 15 (10.3%) 0.001b
OR = 2.8 (1.5 – 5.2)
Voice tremor on exam 71 (35.3%) (n = 201) 38 (26.2%) (n = 145) 0.07b
OR = 1.5 (0.96 – 2.5)
Values represent mean ± standard deviation or number (percentage). For some items, there were missing data and sample size is provided in parentheses
(e.g., n = 198).
*
Performance-based test score was performed as part of a sub-study.





CIRS = Cumulative Illness Rating Scale.
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Table 2
Odds of using a tremor medication
Factors OR (95% CI), p value univariate analysis*
Age in years 1.01 (0.995 – 1.02), p = 0.24
Gender 0.88 (0.58 – 1.35), p = 0.57
White Race 0.96 (0.69 – 1.34), p = 0.79
Education (years) 0.98 (0.93 – 1.03), p = 0.44
Age of tremor onset in years 1.001 (0.99 – 1.01), p = 0.82
Tremor duration in years 1.004 (0.99 – 1.02), p = 0.46
First- or second-degree relative with ET or tremor 1.64 (1.06 – 2.55), p = 0.03
Total tremor score 1.05 (1.01 – 1.08), p = 0.005
Tremor disability scale score 1.01 (1.005 – 1.02), p = 0.001
Performance-based test score 1.02 (1.002 – 1.03), p = 0.02
CIRS score 1.05 (0.99 – 1.12), p = 0.09
Head tremor by history 1.22 (0.79 – 1.90), p = 0.38
Head tremor on exam 1.27 (0.83 – 1.96), p = 0.27
Voice tremor by history 1.38 (0.80 – 2.38), p = 0.25
Voice tremor on exam 1.46 (0.93 – 2.31), p = 0.10
Reported embarrassment 1.98 (1.28 – 3.05), p = 0.002
*
dependent variable = current use of a tremor medication.
CIRS = Cumulative Illness Rating Scale.
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